What Collplant does

CollPlant Biotechnologies Ltd. is a publicly traded regenerative medicine company (NASDAQ: CLGN; TASE: CLPT) headquartered in Rehovot, Israel, founded in 2004 and focused on medical aesthetics, tissue regeneration, and 3D bioprinting. Its core technology is recombinant human type I collagen (rhCollagen) produced in genetically engineered tobacco plants using proprietary plant-based genetic engineering; the company states that no competitors produce collagen from plants or recombinant type I human collagen at commercial scale. This single raw-material platform is vertically integrated into commercial products (Collage rhCollagen, the Collink.3D bioink line including the 50, 50L, and 90 variants, the BioFlex ready-to-print DLP kit launched February 2026, and Vergenix STR soft tissue repair matrix) and a development pipeline comprising photocurable dermal fillers and regenerative breast implants.

The company earns revenue from product sales of rhCollagen and bioinks to biopharma companies and academic/research institutions via direct sales, a U.S.-based cGMP logistics center (operational Q4 2025) serving U.S. and Canada, and expanded European distribution. A second revenue stream has historically come from development milestone payments and licensing royalties under the AbbVie/Allergan agreement, which delivered $26M total between 2021 and 2025 but was terminated by AbbVie in April 2026. Following termination, CollPlant is pursuing independent strategic partnerships for its photocurable dermal filler and regenerative breast implant programs and has executed ~50% workforce reduction to extend cash runway into Q4 2026; management has disclosed substantial doubt about the company's ability to continue as a going concern.

For 2025, GAAP revenue was $2.4M (versus $515K in 2024) and GAAP net loss was $11.5M; cash and equivalents stood at $5.6M at year-end with an accumulated deficit of $124.8M. The company holds an extensive patent portfolio (granted in the U.S., South Korea, and Japan) covering rhCollagen, bioinks, and dermal filler formulations through 2038-2039.

Name

Collplant

Legal name

CollPlant Biotechnologies Ltd.

Website

https://collplant.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

CollPlant is a publicly traded regenerative medicine company that produces plant-derived recombinant human type I collagen (rhCollagen) used in its commercial bioink and soft tissue repair products and in pipeline photocurable dermal fillers and regenerative breast implants, serving biopharma firms, academic researchers, and (historically) AbbVie.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Materials

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Recombinant human collagen
• 3D bioprinting bioinks
• Regenerative medicine materials
• Tissue engineering products
• Medical aesthetics biomaterials

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Product Sales (rhCollagen, BioInks, Vergenix STR): Revenue generated from commercial product sales including rhCollagen (Collage™), bioink products (Collink.3D™), and Vergenix™ STR soft tissue repair matrix. In 2025, product revenues increased driven by rhCollagen product sales and expanded distribution in North America and Europe.
2. Development Milestone Payments: One-time payments received upon achievement of development milestones under collaboration agreements. In 2025, CollPlant received a $2 million milestone payment from AbbVie following a development achievement under the dermal filler development agreement. Historically received $10 million (June 2023) and $14 million (February 2021) from AbbVie.
3. Licensing and Royalty Revenue: Revenue from granting exclusive licenses to use CollPlant's rhCollagen technology in combination with partners' proprietary technologies for product development and commercialization. CollPlant granted AbbVie a worldwide exclusive license for dermal and soft tissue fillers using rhCollagen combined with AbbVie's technology. Royalty streams expected upon commercialization.
4. Registered Direct Offerings (Financing): Equity financing through registered direct offerings and concurrent private placements. CollPlant completed a $3.6 million offering in May/June 2025 and a $2.0 million offering in February 2026, issuing ordinary shares and warrants. These are financing events rather than revenue-generating operations.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

CollPlant develops, manufactures, and commercializes products derived from proprietary plant-based recombinant human type I collagen (rhCollagen) produced in genetically engineered tobacco plants. Its commercial portfolio includes the Collage rhCollagen raw material, the Collink.3D bioink platform (50, 50L, 90 variants), the BioFlex ready-to-print DLP bioprinting kit, and the Vergenix STR soft tissue repair matrix for tendinopathy. Its development pipeline includes photocurable regenerative dermal fillers and regenerative breast implants for medical aesthetics and reconstructive applications.

Product overview

CollPlant develops regenerative medicine products based on recombinant human collagen (rhCollagen) produced through proprietary plant-based genetic engineering technology. The product portfolio includes: Collage™ as the foundational rhCollagen raw material; the Collink.3D™ bioink platform (including 50, 50L, and 90 variants) for 3D bioprinting applications; BioFlex as a ready-to-print DLP bioprinting kit; and Vergenix™ STR for soft tissue repair. The development pipeline includes photocurable dermal fillers and regenerative breast implants. The technology enables tissue engineering, regenerative medicine, drug discovery, and organ manufacturing applications.

Differentiator

Problem solved

Functional benefit

Brands

• Collage™: rhCollagen product derived from plants, bioidentical to native human collagen, offering a safer, purer, and more functional solution than animal-derived collagen.
• Collink.3D™
• Vergenix™ STR
• BioFlex

Products and services

• Collage (rhCollagen) Plant-derived recombinant human type I collagen that is bioidentical to native human collagen, offering a safer, purer, and more functional solution than animal-derived collagen for tissue regeneration applications. Targeted at biopharma companies and academic/research institutions.
• Collink.3D 50 rhCollagen-based bioink designed for 3D bioprinting applications with tunable rheological properties, biocompatibility, and optimal performance at room temperature, enabling precise mimicry of human tissue physical characteristics for tissue regeneration research.
• Collink.3D 50L rhCollagen-based bioink variant for 3D bioprinting with enhanced properties tailored for specific tissue engineering applications.
• Collink.3D 90 rhCollagen-based bioink variant designed for 3D bioprinting applications requiring specific mechanical properties for tissue regeneration.
• BioFlex Ready-to-print rhCollagen-based bioink kit for DLP 3D bioprinting that integrates Collink.3D 50 with proprietary photoactive agents, enabling researchers and industry partners to produce customized, high-performance bioinks with tunable mechanical properties for tissue engineering and regenerative medicine applications without the complexity of multi-component formulation.
• Vergenix STR Advanced soft tissue repair matrix of recombinant human collagen (rhCollagen) combined with autologous Platelet-Rich Plasma (PRP), indicated for the treatment of tendinopathy affecting approximately 2% of the general population and over 40% of sports-related injuries.
• Dermal Fillers (Pipeline) Pipeline rhCollagen-based photocurable dermal and soft tissue filler combining rhCollagen with hyaluronic acid to provide skin lifting, tissue regeneration, and contouring abilities for facial volume restoration, midface deflation, jawline definition loss, skin laxity, and weight-loss-associated facial changes; currently in preclinical development.
• Regenerative Breast Implants (Pipeline) Pipeline regenerative breast implants comprised of proprietary rhCollagen and biomaterials, designed to promote tissue regeneration and degrade in synchronization with newly grown tissue for aesthetic and reconstructive procedures including post-mastectomy breast reconstruction, addressing complications of conventional implants.

Quantifiable outcome

• Collink.3D™ bioink demonstrated superior structured tissue formation compared to Matrigel® in a comparative study, supporting its value as a consistent, tunable, animal-free alternative for advanced tissue engineering.
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• U.S.-Based Logistics CentercoreChannel Partner/ Reseller/ Distributor · 1 October 2025Partnership with a U.S.-based logistics center providing full cGMP-compliant storage and distribution services and clinical supply depot for rhCollagen and BioInk products in the U.S. and Canada. Operational in Q4 2025, this partnership expanded CollPlant's distribution footprint into North America to support growing commercial presence.
• Mayo ClinicminorStrategic or Co-development Partner · 1 October 2025Mayo Clinic researchers used CollPlant's plant-derived rhCollagen to develop the first fully humanized 3D bioprinted human skin model. Results published in Archives of Dermatological Research. The model combines rhCollagen with key human skin cell types, providing an innovative alternative to animal testing for preclinical research in cosmetics, pharmaceuticals, and disease modeling.
• AbbVie / Allergan Industrie SAScoreStrategic or Co-development Partner · 1 February 2021Development and global commercialization agreement for dermal and soft tissue filler products using CollPlant's rhCollagen technology in combination with AbbVie's proprietary technologies. AbbVie was granted a worldwide exclusive license. AbbVie conducted clinical trials initiated in 2023. CollPlant received $2M milestone (Feb 2025), $10M (June 2023), and $14M (Feb 2021). The agreement was terminated by AbbVie in April 2026 following a 5-year collaboration.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Aspect Biosystems: Aspect Biosystems develops 3D bioprinted tissue therapeutics using proprietary bioink and bioprinting technology, overlapping with CollPlant's mission to biofabricate functional human tissues using collagen-based bioinks.
• FibroGen: FibroGen develops therapeutics based on connective tissue growth factors and recombinant collagen technologies, with adjacent applications in tissue regeneration and aesthetics overlapping with CollPlant's rhCollagen platform.

Broad incumbents

• Organogenesis: Organogenesis is an established regenerative medicine company selling skin substitutes and wound-care biologics (e.g., Apligraf), directly comparable to CollPlant's regenerative soft tissue repair and skin/breast tissue programs.
• Galderma: Galderma is a leading aesthetics company (Restylane, Sculptra, etc.) that competes in the dermal filler and regenerative aesthetics market where CollPlant's photocurable rhCollagen filler is positioned, especially for GLP-1-related facial volume loss.
• MTF Biologics: MTF Biologics provides tissue grafts and regenerative biologics for breast reconstruction, sports medicine, and wound care, overlapping with CollPlant's Vergenix STR and regenerative breast implant programs.
• Integra LifeSciences: Integra LifeSciences is a large medical device company with regenerative technology portfolios including dermal regeneration templates and wound-care matrices, competing in overlapping surgical and regenerative categories with CollPlant's breast implant and soft tissue repair programs.

Direct peers

• Advanced BioMatrix: Advanced BioMatrix supplies collagen-based bioinks (including type I collagen) and 3D bioprinting reagents, directly competing with CollPlant's Collink.3D bioink line for academic and biopharma tissue engineering customers.
• Organovo: Organovo is a pioneering 3D bioprinting company developing functional human tissues for therapeutic and research applications, directly comparable to CollPlant in the 3D bioprinting / regenerative tissue engineering category.
• Humabiologics: Humabiologics produces human-derived and recombinant collagen and other extracellular matrix proteins for regenerative medicine and 3D bioprinting, positioning it as a direct competitor to CollPlant's plant-derived rhCollagen platform.
• BICO / CELLINK: BICO (formerly CELLINK) is the leading commercial supplier of bioinks and 3D bioprinting consumables, including collagen-based bioinks, and directly competes with CollPlant's Collink.3D and BioFlex product lines for the same biopharma and academic customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/CollplantBio
• YouTubeyoutube.com/channel/UC_7SlEx2hGdrw75fvVeOgsw
• LinkedInlinkedin.com/company/collplant
• Facebookfacebook.com/191230700958597

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds13 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Collplant